Chilblains with CGRP monoclonal antibody treatment of chronic migraine: A case report and literature review
Abstract
Background Chilblains, characterized by swollen patches and blistering on peripheral extremities, commonly co-occur with Raynaud's Phenomenon. There is limited data to implicate CGRP-targeting migraine medications in these adverse events. Methods We describe one patient who developed chilblains during treatment with the CGRP monoclonal antibodies erenumab followed by galcanezumab and review the current literature on similar outcome reporting. We conducted a literature review in reports of Raynaud's Phenomenon in patients treated with medications of this drug class. Results A 38-year-old female patient developed chilblains while undergoing treatment with erenumab and then galcanezumab. The patient was transitioned to preventive treatment with rimegepant, which she has tolerated well without recurrence of chilblains. We also identified additional case reports, a cohort study, and an analysis of FAERS report data. Conclusion The case reports suggest chilblains can be associated with treatment with CGRP monoclonal antibodies but not during treatment with a CGRP oral antagonist. This adds to the current awareness of potential microvascular complications of migraine therapy, but future safety studies are needed.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.